Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Rigin vs Tripeptide-29

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Rigin and Tripeptide-29 share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Rigin

Cosmetic Clinical Studies

Tripeptide-29

Cosmetic Clinical Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: minimal. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Rigin Tripeptide-29
Class Cosmetic lipopeptide (anti-inflammatory) Cosmetic tripeptide (collagen)
Drug class Dermatologic Dermatologic
Mechanism Suppresses IL-6 secretion by fibroblasts; reduces inflammaging Gly-Pro-Hyp repeat unit; signals fibroblast collagen production
Route Topical Topical
Half-life Topical Topical
Dosage (research) Topical 2-4% Topical 1-5%
Evidence tier Cosmetic Clinical Studies Cosmetic Clinical Studies
Research depth 31 indexed (PubMed 15 · CT 0 · EPMC 16) 1 indexed (PubMed 0 · CT 0 · EPMC 1)
Availability Cosmetic Cosmetic
Reported risks Minimal Minimal

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Rigin or Tripeptide-29?

Rigin and Tripeptide-29 share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.

What is the difference between Rigin and Tripeptide-29?

Rigin is classed as Cosmetic lipopeptide (anti-inflammatory); Tripeptide-29 is classed as Cosmetic tripeptide (collagen). Reported mechanism: Rigin, Suppresses IL-6 secretion by fibroblasts; reduces inflammaging; Tripeptide-29, Gly-Pro-Hyp repeat unit; signals fibroblast collagen production. Reported half-life: Rigin, Topical; Tripeptide-29, Topical. Routes in published studies: Rigin, Topical; Tripeptide-29, Topical.

Which has stronger evidence, Rigin or Tripeptide-29?

Rigin and Tripeptide-29 sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Rigin is graded Cosmetic Clinical Studies, with 2 cited sources on its reference page and 31 indexed studies. Tripeptide-29 is graded Cosmetic Clinical Studies, with 2 cited sources on its reference page and 1 indexed studies.

Which is more accessible, Rigin or Tripeptide-29?

Neither Rigin nor Tripeptide-29 is an FDA-approved drug. Catalog status: Rigin, Cosmetic; Tripeptide-29, Cosmetic.

Are Rigin and Tripeptide-29 ever combined?

Rigin and Tripeptide-29 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…